Abstract
Bosutinib (Bosulif), a new second-generation tyrosine kinase inhibitor targeting the Bcr-Abl protein, was recently approved by the FDA for the treatment of select CML patients with resistance or intolerance to prior therapy. Read about the key trials, dosing and administration, and side effects of this important agent.
